



HEALTHCARE

## **Pharmaceutical Sales Force Strategies**

Driving ROI through best practice in targeting, management, outsourcing and technologies

By Steven Seget

 [Table of Contents](#)

## Steven Seget

Steven Seget is Principal at Delphi Pharma, and provides independent strategic consulting services to the pharmaceutical and biotechnology industries. Steven previously managed the strategic healthcare consulting function at Datamonitor and graduated from the London School of Economics in Accounting & Finance. [sseget@delphipharma.com](mailto:sseget@delphipharma.com)

Delphi Pharma provides strategic, financial and market-based solutions to clients, focusing primarily on the business development and licensing functions. Delphi Pharma combines an extensive research network, applied analytical expertise and an established track record to deliver high value results and measurable impact to its clients. [www.delphipharma.com](http://www.delphipharma.com)

Copyright © 2004 Business Insights Ltd

This Management Report is published by Business Insights Ltd. All rights reserved. Reproduction or redistribution of this Management Report in any form for any purpose is expressly prohibited without the prior consent of Business Insights Ltd.

The views expressed in this Management Report are those of the publisher, not of Business Insights. Business Insights Ltd accepts no liability for the accuracy or completeness of the information, advice or comment contained in this Management Report nor for any actions taken in reliance thereon.

While information, advice or comment is believed to be correct at the time of publication, no responsibility can be accepted by Business Insights Ltd for its completeness or accuracy.

Printed and bound in Great Britain by MBA Group Limited, MBA House, Garman Road, London N17 0HW. [www.mba-group.com](http://www.mba-group.com)

# Table of Contents

## Pharmaceutical Sales Force Strategies

<b>Executive summary</b>	<b>10</b>	
Pharmaceutical sales force landscape	10	
Sizing, structuring and targeting	11	
Recruiting, training and rewarding	12	
Enabling technologies	13	
Outsourcing and partnering	13	
Strategies for increasing promotional ROI	15	
<b>Chapter 1</b>	<b>Pharmaceutical sales force landscape</b>	<b>18</b>
Summary		18
Introduction		19
<b>Changing dynamics of the pharmaceutical industry</b>		<b>19</b>
Resistors to pharmaceutical sales growth		19
Cost containment		20
Generic competition and parallel importing		21
R&D costs and productivity		22
M&A activity		25
Rising commercial expenses		26
Physician detailing		27
Commercial ROI		28
Physician detailing ROI		35
<b>Changing needs of the physician</b>		<b>35</b>
Detailing trends		36
A quieter voice in a louder market		39
Content not frequency		40
The P/RMA code of conduct		41
<b>Impact on the shape and role of the pharmaceutical sales force</b>		<b>42</b>
Organization		43
Management		43
Technologies		44

Collaborations	44
<b>Chapter 2</b>	<b>Sizing, structuring and targeting</b>
	<b>46</b>
<b>Summary</b>	<b>46</b>
<b>Introduction</b>	<b>47</b>
<b>Sales force numbers</b>	<b>49</b>
Trends in headcount	50
US sales force numbers	52
European sales force numbers	54
Japanese sales force numbers	54
Case study: Pfizer	55
<b>Sales force structures</b>	<b>57</b>
Trends in structure	57
US sales force structures	58
European sales force structures	59
Japanese sales force structures	61
<b>Segmenting and targeting</b>	<b>62</b>
Product prioritization	62
Primary care versus specialty	63
<b>Chapter 3</b>	<b>Recruiting, training and rewarding</b>
	<b>65</b>
<b>Summary</b>	<b>65</b>
<b>Introduction</b>	<b>66</b>
<b>Recruiting talent</b>	<b>66</b>
Internal versus external HR	67
<b>Training and development</b>	<b>69</b>
Benchmarking detailing performance	70
Training versus coaching	71
Case study: AstraZeneca	72
<b>Incentives and rewards</b>	<b>74</b>
Trends in remuneration structure	74
Incentive programs	78
Non-cash incentives	80
<b>Chapter 4</b>	<b>Enabling technologies</b>
	<b>83</b>
<b>Summary</b>	<b>83</b>

<b>Introduction</b>	<b>84</b>
<b>Sales force automation</b>	<b>84</b>
Sales force productivity	86
Trends across markets	86
Impact of new technologies	88
Case study: Allergan	90
<b>eDetailing</b>	<b>91</b>
A software solution to increase face-to-face detailing time	92
The ROI of video detailing	93
Enhancing physician relationships through mPrescribing	94
Trends in eDetailing	94
eSampling	96
Integrated web-based solutions	97
<b>Other technologies</b>	<b>98</b>
Laptop	99
PDA	99
Smart phone	100

## **Chapter 5                      Outsourcing and partnering                      104**

<b>Summary</b>	<b>104</b>
<b>Introduction</b>	<b>105</b>
<b>CSOs</b>	<b>105</b>
Trends in use of CSOs	109
Add-on versus replacement	111
Case study: Takeda	112
Background	112
Situation	112
Taking a different path	113
Regional Account Directors (RADs)	114
Ashfield Healthcare	115
ROI	115
<b>Commercial alliances</b>	<b>117</b>
Trends in use of collaborative partnerships	117
Co-promotion	119
Co-marketing	120
Strategic partnerships	121

## **Chapter 6                      Strategies for increasing promotional ROI                      124**

<b>Summary</b>	<b>124</b>
<b>Introduction</b>	<b>125</b>

<b>Measuring ROI</b>	<b>125</b>
Field force productivity	125
Sales force ROI	127
Organization	130
Management	131
Technology	132
Partnering	134
<b>CRM</b>	<b>136</b>
Physician's perceptions	137
Lasting physician relationships	138
Partnering with the patient	139
<b>Best practices</b>	<b>140</b>
Meetings and events	140
Mid-level practitioners	141
Permission-based sales model	142
Case study: Pharma's top-ranked sales force	143

## **Appendix** **146**

<b>Primary research</b>	<b>146</b>
<b>References</b>	<b>148</b>
<b>Index</b>	<b>152</b>

# List of Figures

Figure 1.1:	Resistors to pharmaceutical revenue growth	20
Figure 1.2:	R&D expenditure as a proportion of sales, 1980-2003	24
Figure 1.3:	R&D productivity, 1994-2003	25
Figure 1.4:	Absolute and proportional promotional expenses, 2000-2003	26
Figure 1.5:	Promotional expenses split by source, 2000-2003	27
Figure 1.6:	Commercial ROI by leading pharma company, 2002-2003	30
Figure 1.7:	Commercial ROI by leading biotech company, 2002-2003	32
Figure 1.8:	Commercial ROI by leading specialty company, 2002-2003	34
Figure 1.9:	Trends in the number of detailing visits per sales rep over next 2-3 years	37
Figure 1.10:	Trends in the average length of detailing visits over next 2-3 years	39
Figure 1.11:	Key influences on sales force ROI	42
Figure 2.12:	Impact of US promotional spend on US sales, 2003	47
Figure 2.13:	Impact of US detailing spend on US sales, 2003	48
Figure 2.14:	Impact of US sales force size on US detailing spend, 2003	50
Figure 2.15:	Trends in sales force headcount over next 2-3 years	52
Figure 2.16:	Impact of US sales force size on US sales, 2003	53
Figure 2.17:	Typical US sales force structure, 2003	59
Figure 2.18:	Typical EU sales force structure, 2003	60
Figure 2.19:	Typical Japanese sales force structure, 2003	61
Figure 3.20:	Trends in the proportion of sales force remuneration comprised of basic pay over next 2-3 years	77
Figure 4.21:	Greatest impact on sales force effectiveness over next 2-3 years	89
Figure 4.22:	Uptake of eDetailing across Europe and the US	95
Figure 5.23:	Trends in the use of CSOs over next 2-3 years	110
Figure 5.24:	Trends in the use of collaborative sales forces over next 2-3 years	118
Figure 6.25:	Field force productivity model	127
Figure 6.26:	Sales force ROI model	128
Figure 6.27:	Relative ROI impact of sales force effectiveness strategies	129
Figure 6.28:	Survey respondents split by company type and region	148

# List of Tables

Table 1.1:	Total pharmaceutical R&D expenditure, 1980-2003	22
------------	---	----